Objective: In order to clarify clinical efficacy of commercially available 5-fluorouracil (5-FU) topical cream, a clinical study was conducted.
Methods: Two to three cubic millimetres of 5-FU topical cream (Kyowa, Roche) was applied on 50 cases of various types of cholesteatoma (50 patients) two to five times with the interval of 2 weeks, and its clinical efficacy was evaluated by the criteria we developed.
Results: In total, 59% of the cholesteatomas showed good effect, 29% of them showed fair effect, and the effect was poor in the remaining 12%. It was particularly effective in cholesteatomas in the EAC, attic cholesteatomas with an aerated mastoid, and in recurrent-type cholesteatomas.
Conclusion: 5-FU topical cream appeared effective for the treatment of cholesteatomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anl.2005.05.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
5-FU Weakens Defensive Functions of the Junctional Epithelium.
J Periodontal Res
January 2025
Department of Surgery, Stanford University School of Medicine, Stanford, California, USA.
Aim: To investigate additional factors contributing to the pathophysiology of chemotherapy-induced oral mucositis and periodontitis beyond the systemic immune suppression caused by the chemotherapeutic agent 5-Fluorouracil (5-FU).
Methods: 5-Fluorouracil was topically delivered to the non-keratinized, rapidly proliferating junctional epithelium (JE) surrounding the dentition, and acts as an immunologic and functional barrier to bacterial ingression. Various techniques, including EdU incorporation, quantitative immunohistochemistry (qIHC), histology, enzymatic activity assays, and micro-computed tomographic (μCT) imaging, were employed to analyze the JE at multiple time points following topical 5-FU treatment.
Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma.
Cancers (Basel)
December 2024
Dermatology Department, Complejo Asistencial Universitario de León, 24008 León, Spain.
Cutaneous melanoma is a malignant neoplasm with local and distant metastatic potential. When feasible, surgery is the first line of treatment in locoregionally advanced disease. Topical and intralesional treatments can be an alternative second-line treatment.
View Article and Find Full Text PDFType 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention.
J Clin Invest
January 2025
Department of Dermatology, and.
Article Synopsis
- The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) are increasing, highlighting the urgent need for better prevention methods.
- Topical treatments like calcipotriol and 5-fluorouracil (5-FU) can eliminate actinic keratosis (AK) lesions, but their exact mechanisms weren't clear until recent research.
- A study shows that type 2 immunity, specifically the interaction between thymic stromal lymphopoietin (TSLP) and Th2 cells, is crucial for eliminating premalignant cells and could be targeted for cSCC prevention.
T helper 2 cell-directed immunotherapy eliminates precancerous skin lesions.
J Clin Invest
January 2025
Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
The continuous rise in skin cancer incidence highlights an imperative for improved skin cancer prevention. Topical calcipotriol-plus-5-fluorouracil (calcipotriol-plus-5-FU) immunotherapy effectively eliminates precancerous skin lesions and prevents squamous cell carcinoma (SCC) in patients. However, its mechanism of action remains unclear.
View Article and Find Full Text PDFChemoimmunotherapy-Resistant Ocular Surface Squamous Neoplasia Managed With I-125 Brachytherapy.
Cornea
October 2024
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
Purpose: The purpose of this study was to report the management of chemoimmunotherapy-resistant ocular surface squamous neoplasia (OSSN) with iodine-125 (I-125) brachytherapy.
Methods: A 36-year-old man presented to the clinic with biopsy-proven OSSN that covered ∼70% of the corneal surface and extended to the 6 o'clock position of the inferior limbus of the OS. The visual acuity was 20/20 in the OD and 20/40 in the affected OS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!